## Clinical Context This patient presents with classic symptoms and biochemical evidence of primary hypothyroidism: elevated TSH with low-normal free T4, consistent with overt hypothyroidism. ## Why Start Treatment Immediately? **Key Point:** Once overt hypothyroidism is biochemically confirmed (elevated TSH + low free T4) with compatible clinical symptoms, treatment should begin without delay. Repeat testing is unnecessary and delays symptom relief. **High-Yield:** The diagnosis of overt hypothyroidism is clear when TSH > 5 mIU/L AND free T4 is below the normal range. No further confirmatory testing is needed. ## Dosing Strategy | Factor | Consideration | |--------|---------------| | **Starting dose** | 50 mcg in older patients or those with cardiac disease; 25–50 mcg in symptomatic overt hypothyroidism | | **Titration interval** | 6–8 weeks (allows steady state after each dose adjustment) | | **Target TSH** | 0.5–2.5 mIU/L for most patients | | **Monitoring** | TSH at 6 weeks, then annually once stable | **Clinical Pearl:** In this 52-year-old with no cardiac contraindications and clear overt hypothyroidism, 50 mcg is the standard starting dose. Higher starting doses (100 mcg) risk over-replacement and iatrogenic hyperthyroidism. ## Why Not the Other Options? - **Repeat testing (Option B):** Unnecessary delay when diagnosis is biochemically confirmed; causes prolonged suffering. - **Higher starting dose (Option C):** 100 mcg risks over-replacement in a newly diagnosed patient; standard practice is conservative initiation. - **Imaging/antibodies first (Option D):** Anti-TPO and ultrasound are useful for etiology (Hashimoto's vs. iodine deficiency) but do NOT change immediate management. Treatment begins on biochemical diagnosis alone. **Mnemonic:** **START-TSH** — **S**ymptoms + **T**SH elevated + **A**ppropriate **R**ange of free T4 → **T**reatment **S**tart, **H**ighest priority.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.